For trauma patients with exsanguinating torso hemorrhage, resuscitative endovascular balloon occlusion of the aorta (REBOA) did not reduce mortality, and may have increased 90-day mortality, when ...

For patients with nontraumatic, out-of-hospital cardiac arrest (OHCA), evolving technology in the form of resuscitative endovascular balloon occlusion of the aorta, as well as expanded use of ...

A new technique used to control severe bleeding in injured patients has been found to likely increase the risk of death, according to new research from the University of Aberdeen. The world's first ...

San Antonio, TX ., Pryor Medical Devices (The REBOA Company TM), today announced it has received FDA 510(k) clearance for the sale and distribution of its ER-REBOA TM catheter. REBOA (Resuscitative ...

U.S. Army Medical Research and Development Command Funds FORCE Study to Evaluate Advanced Hemorrhage Control Technology on the Battlefield - Prytime Medical SAN ANTONIO, Nov. 1, 2024 /PRNewswire/ -- ...

BOERNE, Texas, Jan. 7, 2025 /PRNewswire/ -- Prytime Medical, The REBOA Company™, proudly announces the first civilian use of its pREBOA-PRO™ catheter in the European Union, following the device's ...

A new technique used to control severe bleeding in injured patients has been found to increase the risk of death, according to new research from the University of Aberdeen, in Scotland, which was led ...

LONDON, Ontario, June 29, 2021 (GLOBE NEWSWIRE) -- Front Line Medical Technologies, Inc. announced today that the U.S. Food and Drug Administration (FDA) has cleared its COBRA-OS™ (Control of Bleeding ...

REBOA is a minimally invasive technique used by the trauma, critical care and emergency medicine community to temporarily occlude large vessels using a balloon. Pryor Medical Devices has received U.S.